Inflammatory bowel disease treatment costs reduced with IFX biosimilar
September 8th 2022Although further studies are needed to confirm the long-term effects, recent studies have shown the infliximab biosimilar to be a safe, effective, and cost reducing treatment for inflammatory bowel diseases.
Read More